Home » Authors » Rachelle H.B. Fishman

Articles by Rachelle H.B. Fishman

Israeli Chief Scientist Designates Biotech, Nanotech High Priorities

April 6, 2005

By Rachelle H.B. Fishman

Rosetta Genomics Brings In $4M For Preclinical Studies

April 6, 2005

By Rachelle H.B. Fishman

Gamida-Cell's StemEx Drug To Be Developed By Teva

Feb. 23, 2005

By Rachelle H.B. Fishman

Genzyme Sues To Halt TKT's Gaucher's Program In Israel

Feb. 2, 2005

By Rachelle H.B. Fishman

Serono To Eventually Construct Ness Ziona Biotech R&D Center

Jan. 12, 2005

By Rachelle H.B. Fishman

Compugen Establishes Keddem Bioscience To Mine Drug Targets

July 7, 2004

By Rachelle H.B. Fishman

Optimata Raises $1M To Push Virtual Patient Engine Progress

June 16, 2004

By Rachelle H.B. Fishman

Three Initiatives Announced At Bio-Tech Israel 2004 Event

May 19, 2004

By Rachelle H.B. Fishman

BioLineRx Raises $4M Round, Signs In-licensing Agreement

May 19, 2004

By Rachelle H.B. Fishman

With U.S. Rehiring Plans, Quark Biotech Cuts Israeli Employees

April 28, 2004

By Rachelle H.B. Fishman

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...